NantKwest, Inc. (NK) Analysts See $-0.32 EPS

March 14, 2018 - By Darrin Black

 NantKwest, Inc. (NK) Analysts See $ 0.32 EPS

Analysts expect NantKwest, Inc. (NASDAQ:NK) to report $-0.32 EPS on March, 21. The stock decreased 5.81% or $0.25 during the last trading session, reaching $4.05. About 279,126 shares traded or 8.04% up from the average. NantKwest, Inc. (NASDAQ:NK) has declined 40.03% since March 14, 2017 and is downtrending. It has underperformed by 56.73% the S&P500.

NantKwest, Inc. (NASDAQ:NK) Ratings Coverage

Among 7 analysts covering NantKwest (NASDAQ:NK), 4 have Buy rating, 1 Sell and 2 Hold. Therefore 57% are positive. NantKwest had 13 analyst reports since August 24, 2015 according to SRatingsIntel. The company was initiated on Monday, August 24 by Piper Jaffray. The firm has “Sell” rating given on Tuesday, May 16 by Citigroup. Citigroup maintained NantKwest, Inc. (NASDAQ:NK) on Monday, March 14 with “Neutral” rating. The firm earned “Buy” rating on Monday, August 24 by Citigroup. On Thursday, June 2 the stock rating was initiated by Raymond James with “Market Perform”. MLV initiated the stock with “Buy” rating in Monday, August 24 report. The stock of NantKwest, Inc. (NASDAQ:NK) earned “Buy” rating by Jefferies on Monday, August 24. The firm has “Outperform” rating by FBR Capital given on Wednesday, October 28. As per Sunday, August 6, the company rating was maintained by Jefferies. The company was downgraded on Tuesday, January 24 by Jefferies.

NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company has market cap of $321.79 million. The firm develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It currently has negative earnings. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: